$28 Million Verdict in Xarelto Case
$28 Million in damages was awarded to a woman hospitalized after taking the blood thinner drug Xarelto. A Philadelphia jury ordered J&J and Bayer, which jointly developed the product, to pay $1.8 million in actual damages and $26 million in punitive damages. Plaintiff Lynn Hartman took Xarelto for over a year before suffering a gastrointestinal bleeding requiring four (4) blood transfusions and hospitalization in 2014. At trial, ex-FDA Chief David Kessler testified that Xarelto’s warning labels understated the drug’s bleeding risks and didn’t warn doctors that some patients would be at higher risks for bleed outs.
370 deaths have been reported according to the U.S. Food and Drug Administration. The number of Xarelto suits has grown by 27 percent this year with 20,000 existing claims. The drug is Bayer’s top-selling product, generating $3.2 billion in sales last year and $2.5 billion in 2015 for the Leverkusen, Germany-based pharmaceutical company. Bloomberg cites Xarelto as J&J’s third-largest seller, bringing in $2.3 billion in 2016 as the New Brunswick, New Jersey, company seeks to replace revenue from its Remicade arthritis treatment, which lost patent protection a year ago.
Xarelto is an anticoagulant (blood thinner), however, death, strokes, bleeding and blood clots have been linked as side effects of patients taking the drug. The Food and Drug Administration (FDA) has issued two black box warnings to alert of these serious risks. Xarelto is prescribed after surgery to prevent blood clots and pulmonary embolisms, after DVT and PE formation to reduce the risk of further clot formation, and in nonvalvular AFib to reduce the risk of strokes. There is no reversal agent for uncontrolled bleeding while taking Xarelto.
1,200 Xarelto Cases Selected for Trial
Over 20,000 Xarelto cases are filed in state courts, in Philadelphia and consolidated before U.S. District Judge Eldon Fallon in the Eastern District of Louisiana: MDL – 2592 Xarelto Products Liability Litigation | Eastern District. The verdicts in those cases follow:
- December 5, 2017 (Hartman) = Case No. 160503416, Court of Common Pleas of Philadelphia County, Pennsylvania Plaintiff’s Verdict $28 Million
- April 24, 2017 (Boudreaux) – Eastern District of Louisiana, Defense Verdict
- May 30, 2017 (Orr) – Eastern District of Louisiana, Defense Verdict
- August 18, 2017 (Mingo) – Southern District of Mississippi, Defense Verdict
- To Be Announced – Northern District of Texas
Over 1500 Xarelto cases are filed in the Pennsylvania Court of Common Pleas Case ID 150102349 before Judge Arnold New. The cases are categorized by injuries with the trials scheduled as follows:
- Category 1 – GI Bleed/SPAF – November 6, 2017
- Category 1 – GI Bleed/SPAF – January 16, 2018
- Category 2 – GI Bleed/ VTE – January 29, 2018
- Category 2 – GI Bleed/VTE – February 12, 2018
- Category 3 – Brain Bleed – February 22, 2018
- Category 3 – Brain Bleed – March 8, 2018
Xarelto Linked to Complications
Although the uber blockbuster drug has sold billions for developers, Johnson & Johnson, Janssen Pharmaceuticals Inc. and Bayer Corporation, there is no known antidote to the Xarelto bleeding and clotting complications. Plaintiffs have filed claims alleging side effects that include:
- Gastrointestinal Bleeding;
- Retinal Hemorrhages – bleeding in eyes;
- Pulmonary Embolism (PEs) clots in lungs;
- Deep Vein Thrombosis (DVTs) clots in legs;
- Epidural Hematoma (EDH) bleeding in brain;
- Intracranial Hemorrhages – bleeding in brain.
Free Medical Legal Consultation
If you or a loved one has suffered from strokes, bleeding events, blood clots or other side effects while taking Xarelto, you may be eligible for financial compensation. Contact Us before your time runs out. We look forward to hearing from you.